NR4A1: A Key Protein in Metabolism, Immunity, and Cancer

NR4A1 is a protein that sits at a crossroads of cellular decision-making, influencing whether cells grow or die, whether the immune system attacks or stands down, and whether metabolic processes stay balanced or spiral into disease. Known by several aliases including Nur77 and TR3, it belongs to a small family of “orphan” nuclear receptors, so named because scientists have not definitively identified a natural molecule that switches them on the way hormones activate other receptors in the same class. What makes NR4A1 especially interesting, and difficult to study, is that it can play opposite roles depending on where it is in the cell, which tissue it operates in, and what signals surround it. In some cancers it fuels tumor growth; in certain blood cancers it acts as a tumor suppressor. In immune cells it can either restrain harmful inflammation or push T cells into an exhausted, dysfunctional state. That context-dependence is what makes it both a fascinating biological puzzle and a tantalizing drug target.

An Orphan Receptor That Does Not Wait for a Ligand

Most nuclear receptors work like locks that need a specific molecular key: a hormone binds, the receptor changes shape, and gene activity is turned up or down. NR4A1 bends that rule. It shares high structural similarity with its two family members, NR4A2 (Nurr1) and NR4A3 (Nor1), especially in the regions normally responsible for DNA binding and ligand recognition.¹ But NR4A1 carries an unusually powerful activation region near one end of the protein, spanning roughly amino acids 50 to 160, that can switch on gene expression without any ligand at all.² In practical terms, this means NR4A1 is often driven by the signals that cause its own production rather than by a molecule docking into it afterward. When a cell receives a stress signal, an immune stimulus, or a growth factor cue, NR4A1 gene expression spikes rapidly, which is why it is classified as an “immediate early gene.” Once the protein is made, it can go to work on DNA targets right away.

The Mitochondrial Death Switch

One of the most striking things NR4A1 does has nothing to do with its job as a gene regulator. Under certain stress conditions, the protein physically leaves the nucleus and travels to the mitochondria, the energy-producing compartments of the cell. Once there, it binds to Bcl-2, a protein whose normal job is to keep cells alive, and forces Bcl-2 into a shape that instead promotes cell death.³ This conversion triggers the release of cytochrome c from mitochondria, a classic signal for the cell to undergo programmed death, complete with DNA fragmentation and the condensation of genetic material that marks apoptosis.⁴

This translocation is not a one-trick event. Research shows it can also disrupt the normal balance between mitochondrial splitting and fusion, and suppress the cell’s ability to recycle damaged mitochondria, leading to irreversible organelle damage.⁵ This mechanism matters in several disease contexts. In the heart, for example, oxidative stress can push NR4A1 out of the nucleus in cardiomyocytes, driving the kind of cell death that contributes to heart damage after injury.⁴ In cancer cells exposed to certain treatments, the same translocation can be therapeutic, effectively killing tumor cells from within. The challenge is figuring out how to trigger the death switch in cells you want to eliminate while leaving healthy cells alone.

Metabolic Roles in the Liver, Muscle, and Fat

NR4A1 is active in virtually every major metabolic tissue, including the liver, skeletal muscle, pancreas, and fat, where it influences how the body handles sugar, fat, and energy balance.⁶ In the liver, NR4A1 is switched on during fasting and helps regulate the production of new glucose. It also restrains fat accumulation by suppressing SREBP1c, a master regulator of fat-making genes. Mice engineered to express higher levels of NR4A1 in the liver showed lower triglyceride levels and reduced activity of several genes involved in fatty acid synthesis.⁷

In skeletal muscle, the picture connects to early-life programming. A study in mice found that a maternal high-fat diet during pregnancy increased NR4A1 gene expression in offspring muscle, linked to changes in how the gene’s DNA was chemically modified. Offspring that exercised voluntarily on running wheels normalized both the chemical marks on the gene and its expression levels, and their insulin sensitivity improved as a result.⁸ Higher NR4A1 expression in muscle correlated with elevated insulin levels during glucose testing, suggesting it could be involved in programming susceptibility to type 2 diabetes.

NR4A1 also intersects with AMPK, a well-known cellular energy sensor. In one line of research, exposure to polystyrene microplastics activated NR4A1 in the liver, which in turn ramped up the AMPK-autophagy pathway and disrupted normal lipid production, contributing to liver damage.⁹ In diabetic kidney disease, the NR4A1-LKB1-AMPK signaling chain contributes to injury of podocytes, the specialized cells that form the kidney’s filtration barrier. A plant-derived compound called verbascoside was found to relieve that injury by dialing down NR4A1 expression and quieting the downstream AMPK signaling.¹⁰

The Immune System’s Internal Editor

Your immune system must learn to attack genuine threats while leaving your own tissues alone. NR4A1 is deeply embedded in that educational process. During T cell development in the thymus, cells whose receptors bind too strongly to the body’s own molecules need to be eliminated, a process called clonal deletion. NR4A1 and its family member NR4A3 are essential for this step: they drive the expression of BIM, a pro-death protein, and the deletion of self-reactive cells that could otherwise cause autoimmune disease.¹¹ Researchers have even used fluorescent reporters tied to the NR4A1 gene as a real-time gauge of how strongly a developing T cell’s receptor has been stimulated.

Beyond the thymus, NR4A1 is required for an entire subset of blood cells. Patrolling monocytes, which cruise through blood vessels checking for damage, depend on NR4A1 for their very existence. In mice lacking NR4A1, these cells essentially disappear.¹² The remaining precursors in the bone marrow stall during cell division and die. Those patrolling monocytes have an important housekeeping role: they survey the inner lining of blood vessels, detecting damaged endothelial cells, orchestrating their disposal, and cleaning up the debris.¹³

When NR4A1 is absent from the monocyte and macrophage compartment, the consequences extend to vascular disease. Mice lacking NR4A1 in their blood cells and fed a Western diet developed roughly three times as much atherosclerosis as controls. Their macrophages shifted heavily toward a pro-inflammatory profile, producing more tumor necrosis factor-alpha and nitric oxide while making less of the markers associated with tissue repair.¹⁴ Additional research has shown that boosting NR4A1 in vascular cells can suppress CD36, the receptor that macrophages use to gulp up oxidized LDL cholesterol and transform into the foam cells that build up in artery plaques.¹⁵

T Cell Exhaustion and the Promise for Immunotherapy

While NR4A1 helps eliminate dangerous self-reactive T cells during development, its activity in mature T cells creates a problem for cancer treatment. In tumors and chronic infections, CD8+ T cells that should be killing abnormal cells gradually lose their effectiveness, a state called exhaustion. A landmark genome-wide study identified NR4A1 as a central driver of this dysfunction. NR4A1 parks itself at the DNA binding sites of AP-1, a transcription factor that normally activates genes for T cell killing, and blocks AP-1 from doing its job. Overexpressing NR4A1 shuts down effector T cell responses; deleting it restores killer function and improves tumor immunity.¹⁶

More recent work has refined this picture. NR4A1 is highly expressed in progenitor exhausted T cells, the stem-like reservoir that feeds the ongoing immune response during chronic infection and cancer. It promotes the maintenance of this reservoir while actively suppressing genes associated with terminal effector differentiation. Deleting NR4A1 improves tumor control by unleashing more effector activity, though at the cost of reduced long-term T cell maintenance.¹⁷ A separate study found that deleting both NR4A1 and NR4A2 in tumor-infiltrating T cells led to potent tumor eradication, with the treated cells showing not only less exhaustion but also an expanded pool of precursor cells.¹⁸ These findings have made NR4A1 one of the more actively pursued targets in next-generation cancer immunotherapy.

A Paradox in Cancer

NR4A1’s role in cancer is genuinely two-faced, and which face it shows depends on the type of malignancy. In many solid tumors, including non-small-cell lung cancer and rhabdomyosarcoma, NR4A1 is overexpressed and acts as an oncogene. In lung cancer, elevated NR4A1 is linked to tumor recurrence and poorer survival, and knocking the gene down in cell lines reduced proliferation, migration, and invasion.¹⁹ In rhabdomyosarcoma and other solid tumors, NR4A1 drives genes controlling growth, cell movement, and survival.²⁰

In blood cancers the story flips. NR4A1 and NR4A3 function as tumor suppressors in acute myeloid leukemia. Deleting both genes in mice triggers rapid AML development.²¹ Even partially reducing their gene dosage produces a chronic myeloid disease that mimics mixed myelodysplastic/myeloproliferative neoplasms in humans, occasionally progressing to full leukemia.²² The mechanism of silencing in human AML patients appears to involve chemical modification of the gene itself: NR4A1 and NR4A3 promoters are heavily methylated in AML patients compared with healthy individuals, effectively muting the tumor suppressors.²³

Adding another layer, NR4A1’s impact in the tumor microenvironment depends on which immune cell you are looking at and which cancer is involved. In colon cancer, NR4A1 activity in macrophages appears to be a positive prognostic sign, while in melanoma, NR4A1 activity in T cells is associated with worse outcomes, likely because of the exhaustion mechanism described earlier.²⁴ Any drug targeting NR4A1 in cancer would need to account for this cell-type and tissue-type specificity, or risk helping the tumor in one compartment while fighting it in another.

Autoimmune Disease and Fibrosis

The same anti-inflammatory tendencies that make NR4A1 important in atherosclerosis extend to autoimmune and rheumatic conditions. Altered NR4A1 activity has been documented in rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and systemic sclerosis, where it affects immune cell migration, cytokine production, and the overgrowth of synovial tissue that destroys joints. It also influences the generation of regulatory T cells, the immune system’s dedicated peacekeepers, and shapes how dendritic cells activate or suppress broader immune responses.²⁵

In fibrotic diseases, where excessive scar tissue replaces healthy organ structure, NR4A1 acts as a natural brake. It inhibits TGF-beta signaling, one of the most powerful drivers of fibrosis, by assembling a repressor complex on TGF-beta target genes that silences their activity.²⁶ Loss of NR4A1 promotes TGF-beta-driven fibrosis, while its presence restrains pro-fibrotic gene expression. A recent study on idiopathic pulmonary fibrosis found that estrogen can upregulate NR4A1 to counteract TGF-beta-induced lung fibrosis, which may partly explain sex differences in the incidence of this disease.²⁷

NR4A1 in the Brain

NR4A1 is rapidly induced in the brain under stress, and its activity there affects two conditions that get a lot of research attention: Parkinson’s disease and stroke. In a rat model of Parkinson’s disease, the neurotoxin used to kill dopamine-producing neurons also triggered a fast surge in NR4A1 in the substantia nigra, the brain region most affected by the disease. Genetically disrupting NR4A1 reduced dopamine cell loss and also lessened the involuntary movements caused by chronic L-DOPA treatment, the standard drug for Parkinson’s. Conversely, overexpressing NR4A1 in the brain’s movement-control circuits enhanced those abnormal movements.²⁸

In stroke, NR4A1 plays a protective role through a surprising mechanism. Rather than acting as a gene regulator, it works in the cytoplasm of microglia, the brain’s resident immune cells, to destabilize the messenger RNA for TNF, a key inflammatory molecule. Deleting NR4A1 from microglia raises TNF levels and worsens stroke outcomes in mice.²⁹ This is a genuinely unusual function for a nuclear receptor: controlling inflammation not by sitting on DNA in the nucleus but by degrading inflammatory messages out in the cell body. It underscores the point that NR4A1 does not always follow the rules its protein family would predict.

The Drug Development Landscape

Because NR4A1 was long considered an orphan without a natural activator, drug development initially seemed difficult. No one knew what pocket to target. That picture has changed. Several classes of synthetic and natural compounds now bind NR4A1 at different surfaces, producing effects that vary by structure and cellular context. These include cytosporone B and its analogs, bis-indole-derived compounds, the plant-derived triterpenoid celastrol, and certain polyunsaturated fatty acids.³⁰ The compounds have been described as selective NR4A1 modulators, meaning they can act differently depending on what tissue they are in and which binding surface they engage on the protein.

The complexity is illustrated by the cytosporone B analogs. One analog, TMPA, produces the opposite metabolic effect from cytosporone B itself: it releases a kinase called LKB1 from the receptor and sends it out of the nucleus, resulting in lower blood sugar in diabetic mice, whereas cytosporone B raises blood sugar in fasting mice. Another analog, THPN, triggers NR4A1 to leave the nucleus and induce autophagic cell death specifically in melanoma cells. Yet another, PDNPA, works by blocking NR4A1’s interaction with a different partner protein to suppress inflammatory signaling in macrophages.³¹ These compounds remain in preclinical stages, but they demonstrate that it is possible to selectively push NR4A1 toward anti-cancer, anti-inflammatory, or metabolic effects depending on the chemical structure used.

The question of endogenous ligands has not been fully settled. Work on the closely related NR4A3 found that prostaglandins A1 and A2 can directly bind and activate its ligand-binding domain, and that cells overexpressing NR4A3 responded to prostaglandin A2 with strong apoptosis compared to normal cells.³² Whether NR4A1 itself has a comparable natural ligand in human tissues remains an open question, and the answer could reshape how researchers think about drugging this target.

Circadian Connections

NR4A1 does not operate in a vacuum; its expression is tied to the body’s internal clock. In the retina, NR4A1 was identified as a transcriptional target of circadian dopamine signaling, oscillating alongside PGC-1alpha, a master regulator of mitochondrial function, which itself responds to circadian melatonin.³³ This finding fits into a broader pattern: NR4A1 is an immediate early gene, meaning its expression can spike and fall within hours, making it well-suited to respond to daily rhythms of feeding, fasting, and hormone release. The metabolic effects described earlier in the liver and muscle gain an added dimension when you consider that NR4A1 activity probably waxes and wanes throughout the day, potentially linking disrupted sleep schedules or shift work to the metabolic consequences researchers have attributed to this receptor. The circadian angle remains relatively underexplored compared with NR4A1’s cancer and immune biology, but it may turn out to be a piece that connects several of its seemingly unrelated roles.